Event

All events

Maiwald Platinum Partner at the 2025 Life Sciences Strategy Summit on IP & Exclusivity

13 Oct 2025

We are pleased to announce that Maiwald Intellectual Property will participate as a Platinum Partner at the upcoming Life Sciences Strategy Summit on IP & Exclusivity, taking place in the Infinity Hotel & Conference Resort Munich from 13–15 October 2025.

Dr. Eva Ehlich, Partner at Maiwald, will serve as Event Co-Chair and Panel Chair.
She will lead a key session on Antibody Exclusivity Challenges Considering the Post-G2/21 and Amgen vs Sanofi Landscape

The session will address:

  • The role of “surprising technical effect” in antibody patents
  • Impact of G2/21 on inventive step analysis
  • Legal implications of the Amgen vs Sanofi decision
  • IP and ownership challenges in antibody-drug conjugates (ADCs)
  • New approaches to defining the objective technical problem in antibody cases

Dr. Ehlich will be joined by senior legal and scientific representatives from Novartis, Amgen, and Sterne, Kessler, Goldstein & Fox.

In addition, Dr. Anja Fux will chair a session on EPO Board of Appeal Cases and the Effect Upon the Life Sciences Sector (Cases: G1/24, G2/21, T 1977/22, G1/23)

Discussion points include:

  • The implications of G1/24 and G1/23 for the scope and enforceability of life sciences patents
  • The evolving plausibility standard following G2/21
  • T 1977/22 and its relevance to open-range sufficiency

With over 400 participants expected, including in-house counsel and legal experts from originator, generic, and biotech companies, the summit provides a key platform for discussion and strategic exchange at the interface of law, science, and innovation.

More information and the full agenda are available here.

Details

Topic

Maiwald Platinum Partner at the 2025 Life Sciences Strategy Summit on IP & Exclusivity

Date:

13 Oct 2025

Time:

Location:

Infinity Hotel & Conference Resort Munich

Register